Harmony Biosciences Holdings Inc

Harmony Biosciences insider moves: CEO sells shares at a modest gain while holding RSUs, signaling confidence in a strong neurologic drug pipeline and solid valuation.

Harmony Biosciences CFO’s insider sale sparks analysis of the company’s ALS drug pipeline, value‑based pricing, IP strategy and market‑access plans, showing solid fundamentals and neutral investor sentiment.